Capsule Summary Slidesets

Share

Program Content

Activities

  • PACIFIC 2
    PACIFIC-2: Final Analysis of Concurrent Durvalumab + CRT Followed by Consolidation Durvalumab for Unresectable Stage III NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 29, 2024

    Expires: April 28, 2025

  • Subcutaneous Amivantamab
    PALOMA: Phase Ib Trial of Subcutaneous Amivantamab Given Every 4 Wk in Patients With Advanced Solid Tumors
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 02, 2024

    Expires: May 01, 2025

  • FLAURA2 Postprogression Outcomes
    FLAURA2: Postprogression Outcomes of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 03, 2024

    Expires: May 02, 2025

  • DeLLphi-300
    DeLLphi-300: Long-term Follow-up From Phase I Study of Tarlatamab, a DLL3-Targeted Bispecific T-Cell Engager, in Previously Treated SCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 13, 2024

    Expires: May 12, 2025

  • EMPOWER-Lung 3 Part 1
    EMPOWER-Lung 3 Part 1: Patient-Reported Outcomes With First-line Cemiplimab + Chemotherapy + Ipilimumab in Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 13, 2024

    Expires: May 12, 2025

  • RATIONALE 315
    RATIONALE-315: Surgical Outcomes From Phase III Trial of Perioperative Tislelizumab, a PD-1 Inhibitor, Plus Neoadjuvant Chemotherapy in Resectable NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 16, 2024

    Expires: May 15, 2025

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc